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Although some risk factors for accelerated decline in forced expiratory volume in 1 s (FEVi) such as cigarette 
smoking, are well defined, it is not possible to identify those individuals with the most rapid rates of decline. Von 
Willebrand factor (vWF) is a product of both the pulmonary and systemic endothelium, and serum levels are raised 
during episodes of acute bronchitis. We hypothesized that raised serum levels of vWF may indicate sub-clinical 
pulmonary injury and so may predict subsequent accelerated decline in FEVi. The aims of this study were 1. to 
define the prevalence of chronic respiratory symptoms and obstructive airway disease in an inner-city British 
population and 2. to determine whether elevated levels of von Willebrand factor (vWF) identify those individuals at 
risk for more rapid decline in FEVi over time. 
In 1987, all 2013 individuals aged 45 to 74 years at an inner-city general practice were mailed a respiratory 
symptom questionnaire. One in six of the responders were asked to attend for spirometry and for assessment of 
serum vWF. In 1996, those individuals who had spirometry and vWF assessed in 1987 were traced, and repeat 
spirometry was performed. 
In 1987, 1527 of 2013 (758%) individuals completed the questionnaire. Forty-two point two percent of 
responders reported shortness of breath on hills, 34.7% reported wheeze and 31.6% reported mucus 
hypersecretion. Smokers were more likely to report these symptoms. Two hundred and ten of the 251 (84%) 
individuals approached had spirometry and vWF assessed. Eleven percent of these had both an FEVi ~75% 
predicted and a forced expiratory ratio (FEVi forced vital capacity (FVC)) ~70%. Sub-normal spirometry was 
associated with wheeze, mucus hypersecretion, cigarette smoking and increasing age. By 1996, 32 (15%) of the 
original group of 210 individuals had died, and 117 of the remaining 178 (66%) had spirometry repeated. FEVi 
~75% predicted was a strong predictor of interim mortality, independent of age, sex and smoking history. The 
average decline in FEVi was 46.7 ml yr-‘. There was no significant correlation between serum vWF levels and 
subsequent decline in FEVi. 
Chronic respiratory symptoms and spirometric evidence of airflow limitation are common in inner-city residents 
of the U.K., and are associated with smoking history. Much of this disease is unrecognised by health professionals. 
An FEVi < 75% predicted is a strong independent predictor of subsequent mortality. The measurement of serum 
vWF levels is unhelpful in identifying those individuals at increased risk of accelerated decline in FEVi. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) and 
asthma remain significant causes of morbidity and mortal- 
ity in Britain. Cigarette smoking is irrefutably linked to the 
development of COPD (1,2), although the pathophysiolo- 
gical mechanisms remain poorly defined. Fletcher and Peto 
(1) demonstrated that FEVt declines progressively after the 
age of 25-30 at a rate of about 30 ml yr-‘. Cigarette 
smoking roughly doubles this rate of decline, but does not 
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accelerate decline sufficiently to lead to disabling shortness 
of breath unless another factor (or factors) are present. 
These contributing factors are unknown, but are present in 
15-20% of smokers (the so-called ‘susceptible’ smokers) 
(1,2) Bronchial hyper-reactivity and female sex were 
identified as additional risk factors by the U.S. Lung 
Health Study (3), while Fletcher and Peto have shown that 
chronic mucus hypersecretion, while being independently 
due to cigarette smoking, is not a risk factor for airflow 
limitation (1). 
Most studies have demonstrated a recent decline in the 
prevalence of chronic obstructive pulmonary disease 
(COPD) and an increase in the prevalence of asthma (at 
least in children) (4-7), although these changes may in part 
reflect labelling shifts and cohort effects (7). Obstructive 
lung diseases remain generally more common in Britain 
than in other western nations, and there are substantial 
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regional differences within the U.K. (7). In order to reduce 
the prevalence of COPD, it will be necessary to identify and 
eliminate aetiological factors: cigarette smoking aside, these 
remain undefined. 
Von Willebrand factor (vWF) is an endothelial product 
which, when homeostasis is threatened, is released and 
activates platelets through binding to the membrane 
glycoproteins Gpl b and GpIIb-IIIa (8). Irreversible platelet 
binding leads to the formation of a platelet plug. vWF is a 
product of both the systemic and pulmonary endothelium 
(9) and is also released in situations where endothelial 
damage or dysfunction is present or presumed (systemic 
and pulmonary hypertension (10-12) and hypercholester- 
olaemia (13)). vWF is also released, presumably from the 
pulmonary endothelium, in the acute respiratory distress 
syndrome (ARDS), and its release may predate the 
development of clinical or radiological signs of ARDS 
(14-16). As we have found increased plasma levels of vWF 
in patients with acute bronchitis (17) we hypothesized that 
higher serum levels of vWF may indicate sub-clinical 
pulmonary injury, and so may predict a more rapid rate 
of decline in FEV, in subsequent years. 
The aims of this study were 1. to define the prevalence of 
chronic respiratory symptoms and obstructive airway 
disease in an inner-city British population and 2. to 
determine whether elevated blood levels of von Willebrand 
factor (vWF) identify those individuals at risk for more 
rapid decline in FEVi over time. 
Material and methods 
Both components of the study were passed by the East 
Birmingham Health Authority Research and Ethics Com- 
mittee. 
PREVALENCE STUDY 
Subjects 
In Autumn 1987, all 2013 individuals aged 45-74 years 
registered with an inner-city general practice (total practice 
population approximately 9500) were sent a respiratory 
symptom questionnaire and an invitation to attend for 
lung function tests (17). Non-responders were re-mailed 
to a total of three mailings. From those who responded a 
one in six sample was selected (using random number 
tables) to attend for lung function and blood tests. This 
subgroup formed the longitudinal study population (see 
below). 
Methods 
The respiratory symptom questionnaire was adapted from 
that developed by the International Union Against 
Tuberculosis and Lung Disease (IUATLD) (18). The 
questions assessing different parameters (each with Yes 
and No boxes) were: 
1. Shortness of breath on hills - ‘Are you troubled by 
shortness of breath when hurrying on level ground or 
walking up a slight hill?’ 
2. Shortness of breath at night - ‘Are you ever woken at 
night with shortness of breath?’ 
3. Wheeze - ‘Does your chest ever sound whistling or 
wheezing?’ 
4. Mucus hypersecretion - ‘Do you usually bring up any 
phlegm from your chest first thing in the morning or in 
the winter?’ 
5. Asthma - ‘Have you ever had an attack of asthma? 
Smoking histories were self-reported. In those who 
attended for lung function tests, smoking histories were 
obtained and exhaled carbon monoxide levels (Morgan 
Ecocheck) measured. One pack-year was defined as one 
pack of 20 cigarettes smoked per day for 1 yr. Lung 
function (FEVi and FVC) was assessed on one occasion 
using a VitalographTM dry-bellows spirometer, with at least 
two attempts reproducible to within 200 ml or 5% 
(whichever was smaller). Assessment was delayed until 
symptomatic recovery in patients with respiratory infec- 
tions, but inhaled bronchodilators were not used, in 
common with previous studies of this type (19-21). Those 
attending for spirometry had serum collected for assay of 
vWF, using an enzyme linked immunosorbent method (22) 
on three separate venous blood samples, each acquired at 
least a week apart. 
Analysis 
Discreet data are presented as numbers and percentages of 
the totals. Continuous data are presented as means and 
standard deviations. Percent of predicted values for lung 
function were calculated following the 1994 British 
Thoracic Society guidelines (23). Chi-squared tests were 
used to assess differences in questionnaire responses 
according to smoking status for statistical significance. 
Multiple logistic regression analyses (STATA, Stata Corp, 
U.S.A.) were performed to identify questionnaire items 
independently associated with obstructive spirometry 
(FEVJFVC ~70%) and FEVi ~15% predicted. 
LONGITUDINAL STUDY 
Subjects 
The individuals who had lung function and vWF 
assessed in Autumn 1987 formed the longitudinal study 
population. 
Methods 
Follow-up was conducted in Autumn 1996 after a 9 yr 
interval. Patients were traced via their general practitioners 
and the local health authority. Those still in the Midlands 
area of the U.K. were asked to complete the same 
respiratory symptom questionnaire, and were requested to 
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attend for further breathing tests (again with two remin- 
ders). Lung function (FEVr and FVC) was re-assessed by a 
different operator, but using the same VitalographTM 
dry-bellows spirometer and the same methodology as 
in 1987. 
Analysis 
Differences in the prevalence of respiratory symptoms in 
the prevalence study population and the longitudinal study 
population were assessed for statistical significance using 
Chi-squared tests. The characteristics of the populations 
with and without follow-up lung function data in the 
longitudinal study population were compared using ANO- 
VA for normally distributed data, Kruskal-Wallis one way 
analysis of variance for non-parametric data and chi- 
squared tests for discreet variables. The mean of the three 
estimations of vWF (1987) were used in statistical analysis. 
Annualized rate of decline in FEVr was calculated for each 
individual by subtracting the FEVr in 1996 from the FEVr 
in 1987 (in ml) and dividing by the number of intervening 
decimal years (to the nearest month). 
Given the heterogeneity of the study population, we also 
examined change in lung function in terms of annualized 
decline in FEVr height-‘. Multiple logistic regression 
analyses (STATA, Stata Corp, U.S.A.) were performed to 
identify parameters assessed in 1987 which were associated 
with subsequent mortality, and to identify those parameters 
associated with upper quartile loss of FEV, and FEVr 
height-‘. Differences in annualized decline in FEVr 
between different patient groups were assessed for statistical 
significance using Student’s unpaired r-test. Correlation 
coefficients were obtained using the least squares method to 
look for an association between vWF levels and annualized 
decline in FEVr and FEV, height-‘. 
Results 
PREVALENCE STUDY 
One thousand five hundred and twenty seven of 2013 
(758%) individuals completed the questionnaire in 1987. 
The response rate was higher in females than in males 
(78.6% vs. 73.7%, P-cO.02) and in older patients 
(P<O.OOl). The characteristics of the 1527 responders are 
presented by smoking status in Table 1. There was a high 
prevalence of chronic respiratory symptoms with 42.2% of 
responders reporting shortness of breath on hills, 34.7% 
reporting wheeze and 31.6% reporting mucus hypersecre- 
tion. Twenty-one percent of responders reported both 
mucus hypersecretion and shortness of breath on hills. 
Nine percent had a history of asthma. Current smokers and 
ex-smokers were more likely to be male and to report 
wheeze, mucus hypersecretion and shortness of breath on 
walking up a slight hill (Table 1). 
Of the 251 subjects approached to have lung function 
and blood tests, 210 (84%) had spirometry performed and 
serum vWF assayed in Autumn, 1987. The 41 subjects who 
did not have lung function assessed were slightly younger 
(although not statistically significantly so) than the 210 who 
did (median age 55 vs. 61, P=O.O9), but were similar in all 
other respects. The prevalence of chronic respiratory 
symptoms in this subgroup of 210 subjects who formed 
the longitudinal study population was not statistically 
significantly different to that in the prevalence study 
population (Table 1 and Table 2). Pulmonary function 
data reflected the questionnaire findings (Table 2). Nineteen 
percent of patients (28% of men and 10% of women) had 
an FEVt ~75% of predicted and 23% (34% of men and 
13% of women) had evidence of airways obstruction 
(FEVr/FVC < 70%). Twenty-three (11%) patients had both 
an FEV, ~75% of predicted and evidence of airflow 
limitation. Of these, seven (30%) had not seen a doctor 
regarding their chest for more than 2 yr. 
The 39 patients with an FEVr ~75% predicted were 
older (62.6 years V.S. 59.5 years (P=O.O5)), and more likely 
to report wheeze (O.R. 9.8 (3.8-26.4)) and mucus hyperse- 
cretion (4.8(2%1-10.0) than those with normal lung function. 
There was a strong association between smoking status and 
having an FEV, ~75% predicted (3% of never smokers, 
34% of ex-smokers and 13% of current smokers, 
P<O.OOOl). Those with airflow limitation (FEV,/ 
FVC<70%) were older (mean 64.9 years vs. 58.6 years 
(P<OaOOl)), more likely to be male (O.R. 3.6(16-8.3)) and 
had consumed a greater number of pack-years (37.5 vs. 
21.6 (P<O.OOl)). 
TABLE 1. Characteristics of questionnaire responders in 1987 by smoking status (n=1527) 
All subjects Current smokers Ex-smokers Non-smokers 
(n=l527) (n=540) (n=418) (n=569) P 
Median (yr) age 61 61 61 61 0.99 
Female 794 (52%) 234 (43%) 166 (40%) 425 (75%) <O.OOl 
SOB on walking 645 (42%) 259 (48%) 179 (43%) 207 (36%) <O*OOl 
SOB at night 165 (11%) 68 (12%) 42 (10%) 55 (10%) 0.24 
History of wheeze 530 (35%) 292 (54%) 125 (30%) 130 (23%) <O.OOl 
Mucus hypersecretion 482 (32%) 262 (48%) 107 (26%) 113 (20%) <O.OOl 
History of asthma 142 (9%) 47 (9%) 37 (9%) 58 (10%) 0.61 
SOB: shortness of breath. 
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TABLE 2. Characteristics of longitudinal study population in 1987 (n=210) 
Subjects with 
follow-up 
pulmonary Subjects lost Subjects who 
All subjects* function data to follow-up died 
(n=210) (n=117) (n=61) P value? (n=32) P value7 
Median age (yr) 
Female 
Height (cm) 
SOB on walking 
SOB at night 
History of wheeze 
Mucus hypersecretion 
History of asthma 
Current smoker 
Ex-smoker 
Never smoker 
Pack-years 
Carbon monoxide (ppm) 
FEVl (1) 
FEV, % 
FEVt < 75% predicted 
FVC (1) 
FVC % 
FEVt/FVC < 70% 
vWF (u ml-‘) 
61 
111 (53%) 
16.5 (9.6) 
100 (48%) 
24 (11%) 
86 (41%) 
63 (30%) 
27 (13%) 
67 (32%) 
81 (38%) 
62 (30%) 
25.2 (25.7) 
9.4 (10.1) 
2.42 (0.76) 
92.3 (19.7) 
39 (19%) 
3.23 (0.95) 
100.3 (18.2) 
48 (23%) 
1.10 (0.20) 
60 
72 (61%) 
164 (9.6) 
61 (52%) 
15 (13%) 
45 (38%) 
28 (24%) 
17 (14%) 
36 (31%) 
40 (34%) 
41 (35%) 
23.7 (24.8) 
8.8 (9.0) 
2.38 (0.75) 
93.8 (19.2) 
15 (13%) 
3.17 (0.96) 
102.3 (19) 
28 (24%) 
1.10 (0.21) 
61 
32 (52%) 
166 (10.5) 
24 (39%) 
5 (8%) 
23 (38%) 
23 (38%) 
6 (10%) 
20 (33%) 
25 (41%) 
16 (26%) 
23.9 (27.6) 
9.3 (12.3) 
2.56 (0.72) 
94.9 (19.0) 
10 (16%) 
3.33 (1.02) 
100.7 (16.4) 
10 (16%) 
I.08 (0.21) 
0.91 
0.24 
0.16 
0.11 
0.36 
0.99 
0.05 
0.37 
0.78 
0.37 
0.23 
0.99 
0.51 
0.16 
0.74 
0.52 
0.33 
0.57 
0.24 
0.60 
63 
7 (22%) 
168 (7.0) 
15 (47%) 
4 (12%) 
18 (56%) 
12 (38%) 
3 (9%) 
11 (34%) 
16 (50%) 
5 (16%) 
33 (24.3) 
11.5 (8.9) 
2.30 (0.63) 
81.8 (20.0) 
14 (44%) 
3.28 (0.77) 
92.1 (16.8) 
10 (31%) 
1.12 (0.24) 
0.32 
<O.OOl 
0.06 
0.27 
0.64 
0.17 
0.10 
0.57 
0.74 
0.15 
0.06 
0.10 
0.07 
0.22 
<O.Ol 
<O.OOl 
0.58 
0.02 
0.25 
0.68 
*Figures in brackets are either % or standard deviation. 
+Probability that those followed up (n=l17) represent the same population as those lost to follow-up (n=61). 
‘Probability that those who died (n=32) represent the same population as those who lived or were lost to follow-up (n=178). 
SOB shortness of breath. 
LONGITUDINAL STUDY 
In Autumn 1996, 117 (56%) of the study population of 210 
patients had pulmonary function re-assessed. Twenty-two 
(11%) could not be traced. A further 15 (7%) had moved 
from the Midlands area of the U.K., but were confirmed to 
be still alive. Twenty-four (11%) declined to attend for 
repeat spirometry. Thirty-two (15%) had died. 
Deaths 
Subjects who died (Table 2) were statistically significantly 
more likely to be male, to have a lower FEVi (both as 
average value and as % predicted) and to have a lower FVC 
(as % predicted) than survivors. Logistic regression 
analysis revealed FEVi < 75% of predicted to be a strong 
independent predictor of subsequent mortality, even when 
controlling for age, sex and smoking history (odds ratio 
2.8 1 (1 e 14-6.93)). Neither vWF levels nor any questionnaire 
items were independently associated with subsequent 
mortality. Deaths were largely cardiovascular in nature 
rather than respiratory (eight from ischaemic heart disease, 
seven from carcinoma (other than lung), four from 
cerebrovascular accident, three from lung carcinoma, one 
from chronic obstructive pulmonary disease, three from 
other causes and six whose records were unobtainable). 
Lung function decline 
There were few differences between the baseline character- 
istics of groups with and without follow-up pulmonary 
function data, when those who died were excluded 
(Table 2). Thirty-eight percent of those lost to follow up 
had reported mucus hypersecretion in 1987, compared to 
24% of those followed up (P=O.O5). 
Of the 117 patients with longitudinal pulmonary function 
data, the average annualized decline in FEVi was 46.7 ml yr- ’ 
(range: a decline of 175.6 ml yt-’ to a gain of 75.6 ml yr-‘). 
The frequency distribution for annualized decline in FEVl 
inmlyr-’ is presented in Fig. 1. Four patients (3.4%) had a 
higher FEV, in 1996 than in 1987. After consulting their 
GPs it was found that two of these subjects suffered from 
mucus hypersecretion, but none had demonstrable rever- 
sible airway function. The decline in FEV, among never 
smokers, ex-smokers, persistent smokers, quitters, asth- 
matics and those with mucus hypersecretion is presented in 
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FIG. 1. Frequency distribution for annualized decline in FEVi (n=l17). 
TABLE 3. Annualized decline in FEVt among patient subgroups 
FEVi in 1987* FEVt in 1996* Annualised decline in FEVi (ml yr-i)+ 
All patients (n= 117) 2.38 (0.75) 1.96 (0.72) 46.7 (40.7-52.7) 
Never smokers (n=41) 2.24 (0.63) 1.85 (0.65) 43.5 (34.8-52.1) 
Ex-smokers (n=36) 2.66 (0.92) 2.23 (0.85) 47.3 (34.7-59.8) 
Persistent smokers (n=32) 2.29 (0.65) 1.82 (0.60) 52 (434-60.6) 
Quitters (n=8) 2.26 (0.59) 1.89 (0.70) 41.1 (3.3-78.8) 
Asthmatics (n=17) 2.11 (0.57) 1.67 (0.62) 48.9 (37-60.8) 
Mucus hypersecretion (n=28) 2.12 (0.57) 1.77 (0.62) 38.9 (23.8-54) 
*Mean (SD). 
+Mean (95% C.I.). 
Table 3. None of the differences between these subgroups 
were statistically significant. 
Logistic regression analysis indicated that neither vWF 
levels nor any questionnaire items were independently 
associated with maximum (fourth quartile) loss of FEVi (or 
FEV height-‘) when age, sex, smoking status and starting 
FEVi were controlled for. 
There was no significant correlation between vWF and 
subsequent rate of decline in FEVi or FEV heightd2. When 
examined individually, there was no correlation between 
vWF and rate of decline in FEVi in any of the patient 
subgroups. 
Discussion 
A number of conclusions can be drawn from this study in a 
sample of 45-75 year olds living in inner-city Birmingham. 
Chronic respiratory symptoms were very common, and 
spirometric data revealed a high prevalence of airflow 
limitation associated with this symptomatology. Those 
patients with an FEVi ~75% predicted were older and 
more likely to report wheeze and mucus hypersecretion. 
Those with evidence of airflow limitation (FEVi/ 
FVC<75%) were also older and had consumed a greater 
number of pack-years. Much of this disease was unrecog- 
nized. FEVi ~75% of predicted was a strong independent 
predictor of subsequent (largely non-respiratory) mortality. 
The average annualized rate of decline (95% C.I.) in FEVt 
was 46.7 rnls yr-’ (407-52.7), however, serum vWF levels 
were not correlated with subsequent rate of decline. 
A number of potential criticisms need to be addressed. 
One is the representativeness of our study populations, 
given the initial (1987) response rate in the prevalence study 
and the numbers lost to follow-up in the longitudinal study. 
This problem is unavoidable in studies of this nature and 
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can only be minimized through efforts such as the 
distribution of reminders (two in this case). In the 
longitudinal study, interim mortality introduces possible 
biases, but when this group was excluded there were few 
differences between those who were and those who were not 
followed up (Table 2). The only statistically significant 
difference was an increased prevalence of mucus hyperse- 
cretion in the group lost to follow-up (P=O.O5). Impor- 
tantly, however, there were no differences in vWF between 
the three groups, suggesting that our conclusions regarding 
vWF remain valid. 
The prevalence of chronic respiratory symptoms in the 
1527 patients who initially responded in 1987 was surpris- 
ingly high (Table 1) and was reflected in pulmonary 
function data (Table 2). Much of this respiratory disease 
was unrecognized. A study by Littlejohns et al. (6) in south- 
west London, in a slightly younger population (age 40-70, 
n=1444), found an incidence of chronic bronchitis (as 
defined by the Medical Research Council questionnaire) of 
17% in men and 7% women, considerably lower than our 
finding of persistent sputum production in 32.5% of the 
1527 patients from inner-city Birmingham. A recent study 
in central Manchester (24), in a population demographi- 
cally similar to that in our study (mean age 66.1 years, 
n=723), found self-reported asthma or bronchitis to be 
present in 30.0% of the population. Both of these studies 
emphasize the prevalence of unrecognized chronic respira- 
tory disease in these inner-city areas of the U.K. 
One of the strongest independent predictors for sub- 
sequent mortality was FEV, < 75% of predicted, support- 
ing previous observations concerning the importance of a 
low FEVl as an independent risk-factor not only for 
respiratory mortality, but all-cause mortality (25,26). The 
majority of deaths in our population were cardiovascular 
rather than respiratory. The aetiology of this association, 
which has been repeatedly described in the literature, 
remains unknown. 
Among the 117 patients with longitudinal FEVl data the 
estimates of rate of decline in FEVl are in line with those 
described by Fletcher and Peto (1) but are greater than 
described by other (predominantly U.S.) studies (Table 4). 
This may relate to the age of our study population as rate of 
TABLE 4. Annualized decline in FEVI, other studies 
decline in FEV, has been shown to accelerate with age 
(27,28). The small numbers in the patient subgroups listed 
in Table 3 precludes any positive conclusion being made 
regarding the relative rates of decline, according to smoking 
status or the presence of respiratory symptoms. The lack of 
an effect of smoking, may, in addition, relate to a type of 
‘survivor effect’ [similar to that described by Camilli et al. 
(29)] in this relatively elderly population, particularly since 
smoking status and FEVl were important independent 
predictors of interim mortality. 
Our conclusions regarding annualized decline in FEVl 
require some qualification. The main criticisms are that we 
have only two data points, and that our range of starting 
values of FEVl is large, as expected in a heterogeneous 
population. The presence of only two data points precludes 
the use of regression models commonly used in longitudinal 
studies (27) and may contribute to the large range of 
annualized declines in FEVl found in this study. The 
assessment of relative decline in FEV, in a heterogeneous 
population is difficult, and models used to adjust for 
disparate starting FEVls are imperfect (20). The model 
which most satisfactorily controls for body size is FEVl 
height-* (20) and accordingly we have described annual- 
ized decline in FEV, in these terms for comparison with 
serum vWF levels. 
There are some positive factors in the study design which 
deserve mention. Although different operators assessed 
pulmonary function in 1987 and 1996, the methodology 
was standardized and the same spirometer was used 
throughout. Furthermore, although a learning effect is a 
common problem in longitudinal studies and is difficult to 
control for, the 9 yr interval between pulmonary function 
assessments meant that most patients had only a vague 
recollection of their previous visit, minimising the influence 
of learning. 
Although a trend towards accelerated decline in FEVl 
amongst smokers was shown, this trend was not statistically 
significant. This may relate to the selection of a ‘non- 
susceptible’ smoking population through interim mortality, 
and it may be argued that this effect has reduced the power 
of this study to detect an association between risk of 
accelerated decline in FEV, and vWF. However, the 
Authors Year Place 
Annualized decline in FEVl 
(ml yr-‘)+ 
Number Follow-up 
Age range studied 64 Non-smokers Smokers 
Fletcher C. Peto R. (1) 1977 London 50-59 792 8 
Camilli A.E. et al. (29) 1987 Tucson 20-70 1705 10 
Tager I.B. et al. (30) 1988 Boston 40-55 1887 10 
Ware J.H. et al. (31) 1990 6 U.S. cities 45-74 2392 9 
Burchfield C.M. et al. (19) 1995 Honolulu 4568 4451 6 
36 
10 
ml yr-’ less 
than smokers 
35 
36 
22.6 
52 
30 
33.7 
+Mean. 
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absence of even a trend towards showing this association 
for FEVi or FEVi heightd2 suggests that a type 2 statistical 
error is unlikely, but if present, the predictive value of vWF 
would be so slight as to be unhelpful to the clinician 
managing obstructive lung disease. 
In summary, the prevalence of chronic respiratory illness 
in the elderly living in the large cities of the U.K. remains 
high. Much of this disease is unrecognized. FEVt declines 
inexorably with age, but the rate of decline accelerates with 
cigarette smoking in a subgroup of patients. While a low 
FEVt remains a strong risk factor for subsequent respira- 
tory and all-cause mortality, clinicians are currently unable 
to identify the subgroup of patients at risk for more rapid 
decline in FEVt. Measuring serum vWF levels would 
appear unhelpful in this regard. 
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